CIBC Asset Management Inc boosted its holdings in Equifax Inc. (NYSE:EFX – Get Rating) by 9.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 16,386 shares of the credit services provider’s stock after purchasing an additional 1,429 shares during the period. CIBC Asset Management Inc’s holdings in Equifax were worth $2,809,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Equifax by 1.2% in the first quarter. Vanguard Group Inc. now owns 13,036,468 shares of the credit services provider’s stock worth $3,090,947,000 after purchasing an additional 155,572 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Equifax by 6.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 12,546,483 shares of the credit services provider’s stock worth $2,293,245,000 after purchasing an additional 737,642 shares during the last quarter. FMR LLC lifted its stake in Equifax by 14.2% in the second quarter. FMR LLC now owns 4,650,733 shares of the credit services provider’s stock worth $850,060,000 after purchasing an additional 579,519 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Equifax by 29.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,160,261 shares of the credit services provider’s stock valued at $760,413,000 after acquiring an additional 949,408 shares during the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC raised its stake in shares of Equifax by 0.6% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,408,679 shares of the credit services provider’s stock valued at $440,258,000 after acquiring an additional 13,532 shares during the last quarter. 93.84% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
EFX has been the subject of several recent analyst reports. Barclays upped their price objective on shares of Equifax from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, December 2nd. Royal Bank of Canada downgraded shares of Equifax from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $195.00 to $158.00 in a research note on Thursday, October 20th. StockNews.com downgraded shares of Equifax from a “hold” rating to a “sell” rating in a research note on Wednesday, January 11th. Jefferies Financial Group downgraded shares of Equifax from a “buy” rating to a “hold” rating and lowered their price objective for the company from $250.00 to $161.00 in a research note on Wednesday, October 19th. Finally, Stifel Nicolaus upped their price objective on shares of Equifax from $181.00 to $222.00 in a research note on Friday, December 9th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $206.13.
Equifax Trading Down 0.1 %
Equifax Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 15th. Investors of record on Wednesday, November 23rd were given a dividend of $0.39 per share. The ex-dividend date was Tuesday, November 22nd. This represents a $1.56 dividend on an annualized basis and a yield of 0.70%. Equifax’s dividend payout ratio (DPR) is 27.08%.
About Equifax
Equifax, Inc engages in the provision of information solutions and human resources business process outsourcing services. It operates through the following business segments: U.S. Information Solutions, Workforce Solutions and International. The U.S. Information Solutions segment includes consumer and commercial information services, mortgage loan origination information, financial marketing services, and identity management.
Read More
- Get a free copy of the StockNews.com research report on Equifax (EFX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Want to see what other hedge funds are holding EFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Equifax Inc. (NYSE:EFX – Get Rating).
Receive News & Ratings for Equifax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equifax and related companies with MarketBeat.com's FREE daily email newsletter.